Cannabis-sensitive dopaminergic markers in postmortem central nervous system: changes in schizophrenia

Abstract

Background This study investigated if changes in pre-synaptic markers on dopaminergic neurons (dopamine transporter [DAT], tyrosine hydroxylase [TH]) were present in the caudate from subjects with schizophrenia who had Δ 9(−)tetrahydrocannabinol (THC) in their blood at autopsy. These changes were posited because animal studies show that treatment with THC decreases dopamine uptake and TH in the striatum. Methods Studies utilized caudate, obtained postmortem, from 14 schizophrenic and 14 control subjects. [ 3H]mazindol binding to caudate, measured using autoradiography, was taken as a measure of DAT; TH levels were estimated using an antihuman TH antibody and Western blotting. Results There was decreased [ 3H]mazindol binding to DAT in the caudate from the schizophrenic subjects with no detectable blood THC levels (THC(−)) compared with THC(−) control subjects (mean ± SEM: 240 ± 19 vs. 296 ± 14 fmol/mg estimated tissue equivalents, p = .01). There were no significant differences between levels of DAT in the caudate from schizophrenic and control subjects that had THC in their blood. Tyrosine hyroxylase was not different in any diagnostic cohort. Conclusions Our data suggests that DAT is decreased in the caudate from THC(−) subjects with schizophrenia, a change that may be reversed by ingesting THC from cannabis.